Novartis Cancels Plans for Clinical Trials of Gene Therapy OAV201

Novartis Cancels Plans for Clinical Trials of Gene Therapy OAV201

310471

Novartis Cancels Plans for Clinical Trials of Gene Therapy OAV201

Novartis announced it is scrapping plans to move OAV201, an investigational gene therapy for Rett syndrome, into clinical trials. “The totality of the pre-clinical data [on OAV201] does not support a path forward to human clinical trials,” according to the company’s third quarter report for this year. Novartis is “exploring other options for this indication,” according to the report. Recommended Reading October 15, 2021 News by Marta Figueiredo PhD Communication Interventions May Help Rett Patients Better…

You must be logged in to read/download the full post.